A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02079805 |
Recruitment Status
:
Completed
First Posted
: March 6, 2014
Results First Posted
: August 2, 2017
Last Update Posted
: August 2, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Essential Hypertension Complicated by Type 2 Diabetes Mellitus | Drug: Azilsartan Drug: Telmisartan | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 33 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R |
Study Start Date : | June 2014 |
Actual Primary Completion Date : | April 2016 |
Actual Study Completion Date : | April 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Azilsartan 20 mg
Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
|
Drug: Azilsartan
Azilsartan tablets
Other Name: Azilva Tablets
|
Active Comparator: Telmisartan 40 mg
Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
|
Drug: Telmisartan
Telmisartan tablets
Other Name: Micardis Tablets
|
- Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]Change from the start of the treatment period (baseline) at the end of the treatment period (Week 12) was reported. Insulin Resistance Index (HOMA-R) measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405).
- Change in Fasting Blood Glucose From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]Change from baseline in fasting blood glucose values collected at week 12 or final visit relative to baseline was reported.
- Change in Fasting Insulin From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]Change from baseline in fasting insulin values collected at week 12 or final visit relative to baseline was reported.
- Change in Glycosylated Hemoglobin (HbA1c) From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]Change from baseline in the values of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline was reported.
- Change in Homeostasis Model Assessment of Beta Cell Function (HOMA-β) From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]Change from baseline in HOMA-β collected at week 12 or final visit relative to baseline was reported. Homeostasis model assessment of beta cell function measures as following; HOMA-β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}.
- Change in 1,5-anhydroglucitol (1,5-AG) From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]Change from baseline in 1,5-G concentration collected at week 12 or final visit relative to baseline was reported.
- Number of Participants With Treatment-Emergent Adverse Events [ Time Frame: Up to Week 12 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The participant was given the diagnosis of grade I or II essential hypertension and was judged by the principal investigator or investigator that they can be appropriately treated with azilsartan 20 mg and telmisartan 40 mg.
- Sitting systolic blood pressure of ≥ 130 mmHg and < 180 mmHg or sitting diastolic blood pressure of ≥ 80 mmHg and < 110 mmHg at the start of the treatment period (Week 0) Sitting blood pressure will be measured until 2 consecutive stable measurements are obtained (i.e., the difference between 2 measurements: diastolic blood pressure of <5 mmHg and systolic blood pressure of < 10 mmHg) after resting in a sitting position for at least 5 minutes. The average value of the last 2 measurements will be recorded (the first the decimal place is rounded off).
- Type 2 diabetes mellitus
- HbA1c (NGSP (National Glycohemoglobin Standardization Program) value) of < 8.4% during 3 months before informed consent, with a ≤ 0.3% change in HbA1c (peak minus nadir) during 3 months before informed consent
- No change in diet/exercise therapy during the 3 months before the informed consent in a participant who has been on diet/exercise therapy and instructed to improve life style (e.g., diet and exercise)
- Age ≥ 20 years at the time of consent
- Outpatients
- Capable of providing written consent before participation in this study.
Exclusion Criteria:
- Grade III essential hypertension (i.e., sitting systolic blood pressure 180 mmHg or sitting diastolic blood pressure ≥ 110 mmHg), secondary hypertension, or malignant hypertension.
- Grade II essential hypertension (i.e., sitting systolic blood pressure ≥ 160 mmHg or sitting diastolic blood pressure ≥ 100 mmHg) for which antihypertensive drug(s) are used
- Use of oral antihypertensive medication within 2 weeks before the start of the treatment period Participants who are on any antihypertensive agent at the time of informed consent can be enrolled in the study only after 2-week washout following informed consent.
- Use of RAS inhibitors or thiazolidines within 3 months before the start of the treatment period
- Type 1 diabetes mellitus
- Fasting blood glucose of < 180 mg/dL and HOMA-R of ≤ 1.6 at the start of the treatment period (Week 0)
-
Receiving or requiring any of the following at the time of informed consent:
- Insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, or other parenteral hypoglycemic agents
- Combination therapy with 3 or more oral hypoglycemic agents
- Change of antidiabetic medication (including dosage change) within 3 months before the start of the treatment period
-
Having diagnosed/treated any of the following cardiovascular diseases within 3 months before the start of the treatment period:
- Cardiac disease/condition: myocardial infarction, coronary revascularization procedure
- Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack
- Advanced hypertensive retinopathy (retinal bleeding or oozing, papilloedema)
-
Having diagnosed/treated for any of the following cardiovascular diseases more than 3 months before the start of the treatment period, and is now still in unstable condition.
- Cardiac disease/condition: myocardial infarction, coronary revascularization procedure
- Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack
-
Past or current history of any of the following cardiovascular diseases.
- Cardiac valve stenosis
- Angina pectoris requiring medication
- Congestive cardiac failure requiring medication
- Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation)
- Arteriosclerosis obliterans with intermittent claudication or other symptoms
- Have severe ketosis, diabetic coma or precoma, severe infection, or serious trauma
- Clinically evident renal disorder (e.g., eGFR <30 mL/min/1.73 m2)
- Markedly low bile secretion or severe hepatic disorder
- History of hypersensitivity or allergy to azilsartan or telmisartan or to both.
- Presence of hyperkalemia (potassium level ≥ 5.5 mEq/L on laboratory testing)
- Currently participating in any other clinical study.
- Pregnant women, women with possible pregnancy, or breast-feeding women.
- Other participants who are inappropriate for participation in this study in the opinion of the principal investigator or investigator.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02079805
Japan | |
Kyoto-Shi, Kyoto, Japan |
Study Director: | General Manager | Takeda |
Responsible Party: | Takeda |
ClinicalTrials.gov Identifier: | NCT02079805 History of Changes |
Other Study ID Numbers: |
279/NRP-001 U1111-1151-7168 ( Registry Identifier: UTN (WHO) ) AZI-P4-004 ( Other Identifier: Takeda ) JapicCTI-142461 ( Registry Identifier: JapicCTI ) |
First Posted: | March 6, 2014 Key Record Dates |
Results First Posted: | August 2, 2017 |
Last Update Posted: | August 2, 2017 |
Last Verified: | April 2017 |
Additional relevant MeSH terms:
Diabetes Mellitus Hypertension Diabetes Mellitus, Type 2 Insulin Resistance Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Vascular Diseases |
Cardiovascular Diseases Hyperinsulinism Telmisartan Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |